674 related articles for article (PubMed ID: 19938102)
1. Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome.
Kuitwaard K; de Gelder J; Tio-Gillen AP; Hop WC; van Gelder T; van Toorenenbergen AW; van Doorn PA; Jacobs BC
Ann Neurol; 2009 Nov; 66(5):597-603. PubMed ID: 19938102
[TBL] [Abstract][Full Text] [Related]
2. Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barré syndrome: a randomized trial.
Korinthenberg R; Schessl J; Kirschner J; Mönting JS
Pediatrics; 2005 Jul; 116(1):8-14. PubMed ID: 15995024
[TBL] [Abstract][Full Text] [Related]
3. Serum IgG levels as biomarkers for optimizing IVIg therapy in CIDP.
van Doorn PA; Kuitwaard K; Jacobs BC
J Peripher Nerv Syst; 2011 Jun; 16 Suppl 1():38-40. PubMed ID: 21696496
[TBL] [Abstract][Full Text] [Related]
4. IgG Fc N-glycosylation in Guillain-Barré syndrome treated with immunoglobulins.
Fokkink WJ; Selman MH; Dortland JR; Durmuş B; Kuitwaard K; Huizinga R; van Rijs W; Tio-Gillen AP; van Doorn PA; Deelder AM; Wuhrer M; Jacobs BC
J Proteome Res; 2014 Mar; 13(3):1722-30. PubMed ID: 24533874
[TBL] [Abstract][Full Text] [Related]
5. Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barré syndrome.
Buchwald B; Ahangari R; Weishaupt A; Toyka KV
Ann Neurol; 2002 Jun; 51(6):673-80. PubMed ID: 12112071
[TBL] [Abstract][Full Text] [Related]
6. Second IVIg course in Guillain-Barré syndrome patients with poor prognosis (SID-GBS trial): Protocol for a double-blind randomized, placebo-controlled clinical trial.
Walgaard C; Jacobs BC; Lingsma HF; Steyerberg EW; Cornblath DR; van Doorn PA;
J Peripher Nerv Syst; 2018 Dec; 23(4):210-215. PubMed ID: 30151941
[TBL] [Abstract][Full Text] [Related]
7. Intravenous immunoglobulin reduces serum tumor necrosis factor alpha in patients with Guillain-Barre syndrome.
Reuben S; Sumi MG; Mathai A; Nair MD; Radhakrishnan VV
Neurol India; 2003 Dec; 51(4):487-9. PubMed ID: 14742928
[TBL] [Abstract][Full Text] [Related]
8. IVIG treatment and prognosis in Guillain-Barré syndrome.
van Doorn PA; Kuitwaard K; Walgaard C; van Koningsveld R; Ruts L; Jacobs BC
J Clin Immunol; 2010 May; 30 Suppl 1(Suppl 1):S74-8. PubMed ID: 20396937
[TBL] [Abstract][Full Text] [Related]
9. Plasma exchange after initial intravenous immunoglobulin treatment in Guillain-Barré syndrome: critical reassessment of effectiveness and cost-efficiency.
Oczko-Walker M; Manousakis G; Wang S; Malter JS; Waclawik AJ
J Clin Neuromuscul Dis; 2010 Dec; 12(2):55-61. PubMed ID: 21386771
[TBL] [Abstract][Full Text] [Related]
10. Guillain-Barré syndrome in the elderly: clinical, electrophysiological, therapeutic and outcome features.
França MC; Deus-Silva L; de Castro R; Garibaldi SG; Pfeilsticker BH; Nucci A; Marques JF
Arq Neuropsiquiatr; 2005 Sep; 63(3B):772-5. PubMed ID: 16258654
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of Guillain-Barré syndrome with high-dose intravenous immunoglobulins--a comparison with plasma exchange].
Kamei T; Nakagawa H; Uchiyama F; Fukuyama J
Rinsho Shinkeigaku; 1993 Jun; 33(6):660-2. PubMed ID: 8403689
[TBL] [Abstract][Full Text] [Related]
12. [Eczematous reactions after intravenous immunoglobulin therapy in two patients with Guillain-Barré syndrome and a patient with Miller Fisher syndrome].
Tada M; Tada M; Ishiguro H; Yagi E; Hirota K
No To Shinkei; 2003 May; 55(5):401-5. PubMed ID: 12833881
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy for Guillain-Barré syndrome in the US hospitals.
Alshekhlee A; Hussain Z; Sultan B; Katirji B
J Clin Neuromuscul Dis; 2008 Sep; 10(1):4-10. PubMed ID: 18772694
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of intravenous immunoglobulin in multifocal motor neuropathy.
Vlam L; Cats EA; Willemse E; Franssen H; Medic J; Piepers S; Veldink JH; van den Berg LH; van der Pol WL
J Neurol Neurosurg Psychiatry; 2014 Oct; 85(10):1145-8. PubMed ID: 24336791
[TBL] [Abstract][Full Text] [Related]
15. Circulating tumour necrosis factor alpha & soluble TNF receptors in patients with Guillain-Barre syndrome.
Radhakrishnan VV; Sumi MG; Reuben S; Mathai A; Nair MD
Indian J Med Res; 2003 May; 117():216-20. PubMed ID: 14609050
[TBL] [Abstract][Full Text] [Related]
16. Use of immunoglobulin in severe childhood Guillain-Barré syndrome.
Ortiz-Corredor F; Peña-Preciado M
Acta Neurol Scand; 2007 Apr; 115(4):289-93. PubMed ID: 17376129
[TBL] [Abstract][Full Text] [Related]
17. Association of Albumin Levels With Outcome in Intravenous Immunoglobulin-Treated Guillain-Barré Syndrome.
Fokkink WR; Walgaard C; Kuitwaard K; Tio-Gillen AP; van Doorn PA; Jacobs BC
JAMA Neurol; 2017 Feb; 74(2):189-196. PubMed ID: 28027337
[TBL] [Abstract][Full Text] [Related]
18. Markers for Guillain-Barré syndrome with poor prognosis: a multi-center study.
Yamagishi Y; Suzuki H; Sonoo M; Kuwabara S; Yokota T; Nomura K; Chiba A; Kaji R; Kanda T; Kaida K; Ikeda SI; Mutoh T; Yamasaki R; Takashima H; Matsui M; Nishiyama K; Sobue G; Kusunoki S
J Peripher Nerv Syst; 2017 Dec; 22(4):433-439. PubMed ID: 28833828
[TBL] [Abstract][Full Text] [Related]
19. [Guillain-Barré syndrome: epidemiological, clinical and therapeutic insight].
Raphaël JC; Sharshar T
Ann Med Interne (Paris); 2000 May; 151 Suppl 1():1S35-40. PubMed ID: 10896987
[TBL] [Abstract][Full Text] [Related]
20. [Guillain-Barre syndrome and IVIg: does early initiation of treatment influence the mean hospital stay?].
Coll-Cantí J; Alvarez-Ramo R; Dorado L; Guerrero C; Serichol M; Dávalos A; Martínez EM
Neurologia; 2009 May; 24(4):217-9. PubMed ID: 19603290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
